Figure 1.
Viremia and CSIs up to week 14. For each numbered patient in the study (N = 26), there are 6 rows, 1 per target virus. Bars represent the duration of measured viremia (viral load > lower limit of quantification [LLOQ]) per virus. The first panel shows all viremia including viremia that was categorized as CS or causing EOD, the second panel shows duration of viremia categorized as CS (2 patients with CMV), the third panel shows duration of viremia categorized as causing EOD (1 patient with EBV). Nine of 22 patients with viremia had detection of 1 target virus, 5 with 2 viruses, 6 with 3 viruses, and 2 with 4 viruses. Fifteen of 26 patients (58%) had detectable BKV by week 14, making it the most frequently detected virus, followed by EBV (13 of 26 patients, 50%), HHV-6 (6 of 26 patients, 23%), CMV (5 of 26 patients, 19%), AdV (3 of 26 patients, 12%), and JCV (3 of 26 patients, 12%). Notably, there were no CSls from BKV, HHV-6, or JCV, and a single EBV-associated CSI leading to EOD. CS, clinically significant.

Viremia and CSIs up to week 14. For each numbered patient in the study (N = 26), there are 6 rows, 1 per target virus. Bars represent the duration of measured viremia (viral load > lower limit of quantification [LLOQ]) per virus. The first panel shows all viremia including viremia that was categorized as CS or causing EOD, the second panel shows duration of viremia categorized as CS (2 patients with CMV), the third panel shows duration of viremia categorized as causing EOD (1 patient with EBV). Nine of 22 patients with viremia had detection of 1 target virus, 5 with 2 viruses, 6 with 3 viruses, and 2 with 4 viruses. Fifteen of 26 patients (58%) had detectable BKV by week 14, making it the most frequently detected virus, followed by EBV (13 of 26 patients, 50%), HHV-6 (6 of 26 patients, 23%), CMV (5 of 26 patients, 19%), AdV (3 of 26 patients, 12%), and JCV (3 of 26 patients, 12%). Notably, there were no CSls from BKV, HHV-6, or JCV, and a single EBV-associated CSI leading to EOD. CS, clinically significant.

Close Modal

or Create an Account

Close Modal
Close Modal